Actuate Therapeutics, Inc. SEC filings ACTU
Actuate Therapeutics, Inc. has 192 filings in SEC EDGAR's recent list, going back to Oct 8, 2015. Its latest annual report, Form ARS, was filed on Apr 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 6, 2026 | — |
| DEFA14A | Additional proxy material | Apr 6, 2026 | — |
| DEF 14A | Proxy statement | Apr 6, 2026 | May 21, 2026 |
| DEFA14A | Additional proxy material | Apr 9, 2025 | — |
| DEF 14A | Proxy statement | Apr 8, 2025 | May 22, 2025 |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACTU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fort Worth, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1652935
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.